Hydrocortisone succinate

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Hydrocortisone succinate is a corticosteroid used to treat severe allergic reactions, dermatologic diseases, endocrine disorders, gastrointestinal diseases, hematological disorders, neoplastic diseases, nervous system conditions, ophthalmic diseases, renal diseases, respiratory diseases, and rheumatic disorders.

Brand Names

Solu-cortef

Generic Name

Hydrocortisone succinate

DrugBank Accession Number

DB14545

Background

Not Available

Type

Small Molecule

Groups

Approved

Structure

Similar Structures

Weight: Average: 462.539
Monoisotopic: 462.225368055
Chemical Formula: C₂₅H₃₄O₈

Synonyms

Cortisol 21-(hydrogen succinate)
Cortisol succinate
Hydrocortisone hemisuccinate anhydrous
Hydrocortisone hydrogen succinate
Hydrocortisone succinate
Hydroxycortisone succinate

Poor quality drug data slowing you down?

Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.

Download eBook

Poor quality drug data slowing you down?

Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates

Build, train, & validate machine-learning models
with evidence-based and structured datasets.

See how

Build, train, & validate predictive machine-learning models with structured datasets.

See how

Associated Conditions

Indication Type	Indication	Approval Level	Patient Characteristics	Dose Form
Management of	Acquired hemolytic anemias	••••••••••••	•••••• •••••••• •••• •••••••	•••••••••
Adjunct therapy in management of	Acute gouty arthritis	••••••••••••	•••••• •••••••• •••• •••••••	•••••••••
Management of	Ankylosing spondylitis (as)	••••••••••••	•••••• •••••••• •••• •••••••	•••••••••
Management of	Berylliosis	••••••••••••	•••••• •••••••• •••• •••••••	•••••••••
Management of	Bullous dermatitis herpetiformis	••••••••••••	•••••• •••••••• •••• •••••••	•••••••••

Associated Therapies

Palliative Treatment

Contraindications & Blackbox Warnings

Prevent Adverse Drug Events Today

Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.

Learn more

Avoid life-threatening adverse drug events with our Clinical API

Learn more

Pharmacodynamics

Not Available

Mechanism of action

Not Available

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects

Improve decision support & research outcomes

With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!

See the data

Improve decision support & research outcomes with our structured adverse effects data.

See a data sample

Toxicity

Not Available

Pathways

Not Available

Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">

Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

Drug	Interaction
Integrate drug-drug interactions in your software
Abametapir	The serum concentration of Hydrocortisone succinate can be increased when it is combined with Abametapir.
Abatacept	The risk or severity of adverse effects can be increased when Abatacept is combined with Hydrocortisone succinate.
Abemaciclib	The metabolism of Abemaciclib can be increased when combined with Hydrocortisone succinate.
Acalabrutinib	The metabolism of Acalabrutinib can be increased when combined with Hydrocortisone succinate.
Acarbose	The risk or severity of hyperglycemia can be increased when Hydrocortisone succinate is combined with Acarbose.

Food Interactions

No interactions found.

Products

Drug product information from 10+ global regions

Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.

Access now

Access drug product information from over 10 global regions.

Access now

Product Ingredients

Ingredient	UNII	CAS	InChI Key
Hydrocortisone sodium succinate	50LQB69S1Z	125-04-2	HHZQLQREDATOBM-CODXZCKSSA-M
Hydrocortisone succinate monohydrate	LIU00Z1Z84	83784-20-7	AFLWPAGYTPJSEY-CODXZCKSSA-N

Active Moieties

Name	Kind	UNII	CAS	InChI Key
Hydrocortisone	unknown	WI4X0X7BPJ	50-23-7	JYGXADMDTFJGBT-VWUMJDOOSA-N

Brand Name Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
A-hydrocort Inj 1000mg/8ml	Powder, for solution	1 g / vial	Intramuscular; Intravenous	Hospira Healthcare Ulc	1993-12-31	2012-08-03
A-hydrocort Inj 100mg/2ml	Powder, for solution	100 mg / vial	Intramuscular; Intravenous	Hospira Healthcare Ulc	1992-12-31	2012-08-03
A-hydrocort Inj 250mg/2ml	Powder, for solution	250 mg / vial	Intramuscular; Intravenous	Hospira Healthcare Ulc	1992-12-31	2012-08-03
A-hydrocort Inj 500mg/4ml	Powder, for solution	500 mg / vial	Intramuscular; Intravenous	Hospira Healthcare Ulc	1992-12-31	2012-08-03
Hydrocortisone Sodium Succinate for Injection	Powder, for solution	500 mg / vial	Intramuscular; Intravenous	TEVA Canada Limited	1994-12-31	2018-04-30

Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End	Region	Image
A-hydrocort	Injection, powder, lyophilized, for solution	100 mg/2mL	Intramuscular; Intravenous	Hospira, Inc.	2006-12-14	2010-07-01

Chemical Identifiers

UNII: IHV1VP592V
CAS number: 2203-97-6
InChI Key: VWQWXZAWFPZJDA-CGVGKPPMSA-N
InChI: InChI=1S/C25H34O8/c1-23-9-7-15(26)11-14(23)3-4-16-17-8-10-25(32,24(17,2)12-18(27)22(16)23)19(28)13-33-21(31)6-5-20(29)30/h11,16-18,22,27,32H,3-10,12-13H2,1-2H3,(H,29,30)/t16-,17-,18-,22+,23-,24-,25-/m0/s1
IUPAC Name: 4-{2-[(1R,3aS,3bS,9aR,9bS,10S,11aS)-1,10-dihydroxy-9a,11a-dimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl]-2-oxoethoxy}-4-oxobutanoic acid
SMILES: [H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C

References

General References

Not Available

External Links

KEGG Drug: D01442
ChemSpider: 15760
BindingDB: 50016931
RxNav: 21651
ChEBI: 31677
ChEMBL: CHEMBL977
ZINC: ZINC000004097472
Wikipedia: Hydrocortisone_hemisuccinate

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">

Phase	Status	Purpose	Conditions	Count
4	Completed	Treatment	Septic Shock	2
4	Completed	Treatment	Shock	1
4	Completed	Treatment	Ulcerative Colitis	1
4	Not Yet Recruiting	Treatment	Sepsis / Septic Shock / Shock / Systemic Inflammatory Response Syndrome (SIRS)	1
4	Recruiting	Other	Addison's Disease	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage Forms

Form	Route	Strength
Injection, powder, lyophilized, for solution	Intramuscular; Intravenous	100 mg/2mL
Injection, powder, for solution		100 mg
Injection	Intramuscular; Intravenous	100 mg
Injection	Intramuscular; Intravenous
Powder, for solution	Intramuscular; Intravenous	100 mg / vial
Powder, for solution	Intramuscular; Intravenous	250 mg / vial
Powder, for solution	Intramuscular; Intravenous	500 mg / vial
Powder		100 mg/1vial
Powder, for solution	Intramuscular; Intravenous	1 g / vial
Injection, powder, for solution
Solution	Auricular (otic)
Injection, powder, lyophilized, for solution	Intravenous	100 mg
Injection, powder, for solution	Intramuscular; Intravascular	100 mg/2mL
Injection, powder, for solution	Intramuscular; Intravascular	1000 mg/8mL
Injection, powder, for solution	Intramuscular; Intravascular	250 mg/2mL
Injection, powder, for solution	Intramuscular; Intravascular	500 mg/4mL
Injection, powder, for solution	Intramuscular; Intravenous	100 mg/2mL
Injection, powder, for solution	Intramuscular; Intravenous	1000 mg/8mL
Injection, powder, for solution	Intramuscular; Intravenous	250 mg/2mL
Injection, powder, for solution	Intramuscular; Intravenous	500 mg/4mL
Injection, powder, for solution	Intramuscular; Intravenous	100 mg

Prices

Not Available

Patents

Not Available

Properties

State

Not Available

Experimental Properties

Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.0653 mg/mL	ALOGPS
logP	2.17	ALOGPS
logP	1.54	Chemaxon
logS	-3.8	ALOGPS
pKa (Strongest Acidic)	3.66	Chemaxon
pKa (Strongest Basic)	-2.8	Chemaxon
Physiological Charge	-1	Chemaxon
Hydrogen Acceptor Count	7	Chemaxon
Hydrogen Donor Count	3	Chemaxon
Polar Surface Area	138.2 Å²	Chemaxon
Rotatable Bond Count	7	Chemaxon
Refractivity	117.44 m³·mol^-1	Chemaxon
Polarizability	48.68 Å³	Chemaxon
Number of Rings	4	Chemaxon
Bioavailability	1	Chemaxon
Rule of Five	Yes	Chemaxon
Ghose Filter	Yes	Chemaxon
Veber's Rule	No	Chemaxon
MDDR-like Rule	Yes	Chemaxon

Predicted ADMET Features

Not Available

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	splash10-004j-0004900000-e530faeb68007ef36ea0
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	splash10-003s-1009000000-52019723ed10df964359
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	splash10-002b-3525900000-842096195ef2b1ea2929
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	splash10-0089-3009000000-9502a41e3c151e29e4c5
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	splash10-03dl-1925100000-63c659c826d00d1e15d3
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	splash10-00di-9004100000-e03286a590f5c34f5717
Predicted 1H NMR Spectrum	1D NMR	Not Applicable
Predicted 13C NMR Spectrum	1D NMR	Not Applicable

Chromatographic Properties

Collision Cross Sections (CCS)

Adduct	CCS Value (Å²)	Source type	Source
[M-H]-	228.8830037	predicted	DarkChem Lite v0.1.0
[M+H]+	226.7988037	predicted	DarkChem Lite v0.1.0
[M+Na]+	225.8376037	predicted	DarkChem Lite v0.1.0

Enzymes

Details1. Cytochrome P450 3A4

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Substrate
Inducer

General Function: Vitamin d3 25-hydroxylase activity
Specific Function: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name: CYP3A4
Uniprot ID: P08684
Uniprot Name: Cytochrome P450 3A4
Molecular Weight: 57342.67 Da

References

Joellenbeck L, Qian Z, Zarba A, Groopman JD: Urinary 6 beta-hydroxycortisol/cortisol ratios measured by high-performance liquid chromatography for use as a biomarker for the human cytochrome P-450 3A4. Cancer Epidemiol Biomarkers Prev. 1992 Nov-Dec;1(7):567-72. [Article]
Litt J. (2016). Litt's Drug eruption & reaction manual (22nd ed.). CRC Press LLc.

Details2. Cytochrome P450 2C8

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Inducer

General Function: Steroid hydroxylase activity
Specific Function: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name: CYP2C8
Uniprot ID: P10632
Uniprot Name: Cytochrome P450 2C8
Molecular Weight: 55824.275 Da

References

Bauersachs J, Christ M, Ertl G, Michaelis UR, Fisslthaler B, Busse R, Fleming I: Cytochrome P450 2C expression and EDHF-mediated relaxation in porcine coronary arteries is increased by cortisol. Cardiovasc Res. 2002 Jun;54(3):669-75. [Article]
Matoulkova P, Pavek P, Maly J, Vlcek J: Cytochrome P450 enzyme regulation by glucocorticoids and consequences in terms of drug interaction. Expert Opin Drug Metab Toxicol. 2014 Mar;10(3):425-35. doi: 10.1517/17425255.2014.878703. Epub 2014 Jan 23. [Article]

Details3. Cytochrome P450 11B1, mitochondrial

Kind: Protein
Organism: Humans
Pharmacological action: No
Actions: Substrate

General Function: Steroid 11-beta-monooxygenase activity
Specific Function: Has steroid 11-beta-hydroxylase activity. In addition to this activity, the 18 or 19-hydroxylation of steroids and the aromatization of androstendione to estrone have also been ascribed to cytochro...
Gene Name: CYP11B1
Uniprot ID: P15538
Uniprot Name: Cytochrome P450 11B1, mitochondrial
Molecular Weight: 57572.44 Da

References

Freel EM, Shakerdi LA, Friel EC, Wallace AM, Davies E, Fraser R, Connell JM: Studies on the origin of circulating 18-hydroxycortisol and 18-oxocortisol in normal human subjects. J Clin Endocrinol Metab. 2004 Sep;89(9):4628-33. doi: 10.1210/jc.2004-0379. [Article]

Details4. Cytochrome P450 11B2, mitochondrial

Kind: Protein
Organism: Humans
Pharmacological action: No
Actions: Substrate

General Function: Steroid 11-beta-monooxygenase activity
Specific Function: Preferentially catalyzes the conversion of 11-deoxycorticosterone to aldosterone via corticosterone and 18-hydroxycorticosterone.
Gene Name: CYP11B2
Uniprot ID: P19099
Uniprot Name: Cytochrome P450 11B2, mitochondrial
Molecular Weight: 57559.62 Da

References

Freel EM, Shakerdi LA, Friel EC, Wallace AM, Davies E, Fraser R, Connell JM: Studies on the origin of circulating 18-hydroxycortisol and 18-oxocortisol in normal human subjects. J Clin Endocrinol Metab. 2004 Sep;89(9):4628-33. doi: 10.1210/jc.2004-0379. [Article]

Drug created at July 12, 2018 21:25 / Updated at February 20, 2024 23:55

Hydrocortisone succinate

Identification

Structure for Hydrocortisone succinate (DB14545)

Pharmacology

Interactions

Products

Categories

Chemical Identifiers

References

Clinical Trials

Pharmacoeconomics

Properties

Spectra

Collision Cross Sections (CCS)

Enzymes

References

References

References

References